Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

sTRAIL Receptor-2 Human E. coli

  • Regulatory status:RUO
  • Type:Recombinant protein
  • Source:E. coli
  • Other names:soluble TRAIL Receptor-2, DR5, TNFRSF10B, KILER, TRICK2A, TRICKB
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RBG10332010 10 µg
RBG10332050 50 µg
RBG10332100 100 μg
PubMed Product Details
Technical Data


Recombinant protein


TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic “death domain,” which can activate the cell's apoptotic machinery. These receptors are activated by binding to either membrane-anchored or soluble TRAIL/Apo2L. The DR4 and DR5 receptors are both produced as type I transmembrane proteins, which contain an extracellular domain, a transmembrane domain, and a cytoplasmic domain. The recombinant soluble forms of DR4 and DR5 consist of the TNFR-homologous, cysteine-rich portion of their respective extracellular domains. Recombinant Human soluble TRAIL Receptor-2/DR5 is a 14.9 kDa protein (133 amino acid residues) consisting of the TNFR-homologous, cysteine-rich portion of the extracellular domain.

Amino Acid Sequence



E. coli



Biological Activity

sTRAIL Rec 2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/mL) but in the presence of TRAIL Rec 2, TRAIL-induced TNF is suppressed.


Endotoxin level is <0.1 ng/μg of protein (<1EU/μg).


Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1–1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at –20°C to –80°C.




Research topic


Related Products Docs